Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

Exclusion Criteria

• •1. History or presence of any clinically relevant medical condition that could affect the participant's safety or interfere with the objectives of the study
• •2. Presence or history of lung disease, eg, asthma, chronic obstructive pulmonary disease
• •3. Clinically significant abnormality on 12-lead ECG including prolonged corrected QT interval by Fredericia (\>450 msec men or \>470 msec women)
• •4. Use of prescribed or nonprescribed medications or herbal remedies within 28 days of first dosing and during the study with the exception of
• •1. hormone replacement therapy (HRT)
• •2. contraception
• •3. occasional use of paracetamol
• •5. Positive hepatitis B surface antigen, hepatitis C antibodies, HIV-1 or -2 antibodies
• •6. Positive drugs of abuse, smoking, or alcohol test at Screening
• •7. History of alcohol or drug misuse
• •8. Pregnant and lactating women
• •9. Prior recovery from recent infection, including but not limited to COVID-19, within the last 14 days before first dosing with IP
• •10. History of hypersensitivity to any constituents of the IMP or LPS
• •11. Any clinically significant allergy
• •12. Participation in a clinical study with an IP within 3 months or 5 half-lives before first dosing, whichever is longer
• •13. Employees of the sponsor or employees or relatives of the investigator